RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Loading...
Loading...
RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's
AGN
DARPin may solidify the longer-term market position for Regeneron's
REGN
Eylea. The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's." RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019. RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...